<?xml version="1.0" encoding="UTF-8"?>
<ReportSnapshot Major="1" Minor="0" Revision="1">
	<CoIDs>
		<CoID Type="RepNo">EE147</CoID>
		<CoID Type="CompanyName">4d Pharma PLC</CoID>
	</CoIDs>
	<Issues>
		<Issue ID="1" Type="C" Desc="Common Stock" Order="1">
			<IssueID Type="Name">Ordinary Shares</IssueID>
			<IssueID Type="Ticker">DDDD</IssueID>
			<IssueID Type="CUSIP">G3654S104</IssueID>
			<IssueID Type="ISIN">GB00BJL5BR07</IssueID>
			<IssueID Type="RIC">DDDD.L</IssueID>
			<IssueID Type="SEDOL">BJL5BR0</IssueID>
			<IssueID Type="DisplayRIC">DDDD.L</IssueID>
			<IssueID Type="InstrumentPI">152658592</IssueID>
			<IssueID Type="QuotePI">152873333</IssueID>
			<Exchange Code="SEA" Country="GBR">SEATS (AIM Market)</Exchange>
		</Issue>
	</Issues>
	<CoGeneralInfo>
		<CoStatus Code="1">Active</CoStatus>
		<CoType Code="EQU">Equity Issue</CoType>
		<LastModified>2015-09-30</LastModified>
		<LatestAvailableAnnual>2014-12-31</LatestAvailableAnnual>
		<LatestAvailableInterim>2015-06-30</LatestAvailableInterim>
		<Employees LastUpdated="2014-12-31">13</Employees>
		<SharesOut Date="2016-02-15" TotalFloat="44122544.0">64775801.0</SharesOut>
		<ReportingCurrency Code="GBP">British Pounds</ReportingCurrency>
		<MostRecentExchange Date="2016-02-22">0.70681</MostRecentExchange>
	</CoGeneralInfo>
	<TextInfo>
		<Text Type="Business Summary" lastModified="2014-07-18T04:27:35">4d Pharma PLC is a pharmaceutical company. The Company has secured a project, in the field of live biotherapeutics and microbiomics 4d pharma has acquired its first asset in this field, a 46% stake in GT Biologics Limited. The principal activity of GT Biologics is research and development of biological therapeutics. In June 2014, 4d Pharma Plc acquired a further 37.5% of the issued share capital of GT Biologics ltd. In July 2014, 4d Pharma PLC acquired the entire issued share capital of The Microbiota Company Limited.</Text>
		<Text Type="Financial Summary" lastModified="2015-09-30T13:53:53">BRIEF: For the six months ended 30 June 2015, 4d Pharma PLC revenues decreased from L117K to L0K. Net loss totaled L4.1M vs. income of L499K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Operating expenses increase from L684K to L4.5M (expense), Gain on remeasurement of equity interest decrease from L1.4M (income) to L0K.</Text>
	</TextInfo>
	<contactInfo lastUpdated="2016-02-10T02:10:19">
		<streetAddress line="1">74 GARTSIDE STREET</streetAddress>
		<streetAddress line="2"></streetAddress>
		<streetAddress line="3"></streetAddress>
		<city>MANCHESTER</city>
		<state-region></state-region>
		<postalCode>M3 3EL</postalCode>
		<country code="GBR">United Kingdom</country>
		<contactName></contactName>
		<contactTitle></contactTitle>
		<phone>
			<phone type="mainphone">
				<countryPhoneCode>44</countryPhoneCode>
				<city-areacode>161</city-areacode>
				<number>8376205</number>
			</phone>
			<phone type="mainfax">
				<countryPhoneCode>44</countryPhoneCode>
				<city-areacode>161</city-areacode>
				<number>8376201</number>
			</phone>
		</phone>
	</contactInfo>
	<webLinks lastUpdated="2014-02-25T08:59:35"><webSite mainCategory="Home Page">http://www.4dpharmaplc.com</webSite><eMail mainCategory="Company Contact/E-mail">info@4dpharmaplc.com</eMail></webLinks>
	<peerInfo lastUpdated="2016-02-10T02:10:19">
		<IndustryInfo>
			<Industry type="TRBC" order="1" reported="0" code="5620201011" mnem="">Bio Therapeutic Drugs</Industry>
			<Industry type="NAICS" order="1" reported="0" code="325412" mnem="">Pharmaceutical Preparation  Manufacturing</Industry>
			<Industry type="SIC" order="1" reported="0" code="2834" mnem="">Pharmaceutical Preparations</Industry>
		</IndustryInfo>
	</peerInfo>
	<officers>
		<officer rank="1" since="NA">
			<firstName>Duncan</firstName>
			<mI>J.</mI>
			<lastName>Peyton</lastName>
			<age>45 </age>
			<title startYear="NA" startMonth="" startDay="" iD1="CEO" abbr1="CEO" iD2="EDR" abbr2="Exec. Dir.">Chief Executive Officer, Executive Director</title>
		</officer>
		<officer rank="2" since="NA">
			<firstName>Alexander</firstName>
			<mI>James</mI>
			<lastName>Stevenson</lastName>
			<age>43 </age>
			<title startYear="NA" startMonth="" startDay="" iD1="CSO" abbr1="CSO" iD2="EDR" abbr2="Exec. Dir.">Chief Scientific Officer, Executive Director</title>
		</officer>
		<officer rank="3" since="01/18/2014">
			<firstName>Laurence</firstName>
			<mI></mI>
			<lastName>Dale</lastName>
			<age></age>
			<title startYear="2014" startMonth="01" startDay="18" iD1="SEC" abbr1="Secy." iD2="" abbr2="">Company Secretary</title>
		</officer>
	</officers>
	<Ratios PriceCurrency="GBP" ReportingCurrency="GBP" ExchangeRate="1.00000" LatestAvailableDate="2014-12-31">
		<Group ID="Price and Volume">
			<Ratio FieldName="NPRICE" Type="N">9.25000</Ratio>
			<Ratio FieldName="NHIG" Type="N">10.83630</Ratio>
			<Ratio FieldName="NLOW" Type="N">5.20000</Ratio>
			<Ratio FieldName="PDATE" Type="D">2016-02-23T00:00:00</Ratio>
			<Ratio FieldName="VOL10DAVG" Type="N">0.07764</Ratio>
			<Ratio FieldName="EV" Type="N">567.34610</Ratio>
		</Group>
		<Group ID="Income Statement">
			<Ratio FieldName="MKTCAP" Type="N">599.17610</Ratio>
			<Ratio FieldName="AREV" Type="N">0.00000</Ratio>
			<Ratio FieldName="AEBITD" Type="N">-3.00200</Ratio>
			<Ratio FieldName="ANIAC" Type="N">-2.02100</Ratio>
		</Group>
		<Group ID="Per share data">
			<Ratio FieldName="AEPSXCLXOR" Type="N">-0.04812</Ratio>
			<Ratio FieldName="AREVPS" Type="N">0.00000</Ratio>
			<Ratio FieldName="ABVPS" Type="N">0.70965</Ratio>
			<Ratio FieldName="ACSHPS" Type="N">0.61103</Ratio>
			<Ratio FieldName="ACFSHR" Type="N">-0.05395</Ratio>
			<Ratio FieldName="ADIVSHR" Type="N">0.00000</Ratio>
		</Group>
		<Group ID="Other Ratios">
			<Ratio FieldName="AGROSMGN" Type="N">-99999.99000</Ratio>
			<Ratio FieldName="AROEPCT" Type="N">-10.96435</Ratio>
			<Ratio FieldName="APR2REV" Type="N">-99999.99000</Ratio>
			<Ratio FieldName="APEEXCLXOR" Type="N">-99999.99000</Ratio>
			<Ratio FieldName="APRICE2BK" Type="N">13.03466</Ratio>
			<Ratio FieldName="Employees" Type="N">13</Ratio>
		</Group>
	</Ratios>
	<ForecastData ConsensusType="" CurFiscalYear="" CurFiscalYearEndMonth="" CurInterimEndCalYear="" CurInterimEndMonth="" EarningsBasis="">
		<Ratio FieldName="ConsRecom" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="TargetPrice" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjLTGrowthRate" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjPE" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjSales" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjSalesQ" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjEPS" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjEPSQ" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjProfit" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjDPS" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
	</ForecastData>
</ReportSnapshot>
